Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07335341
Recruiting Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341 · tracked via the Priya Life Science USA tracker
Sponsor
Medtronic Endovascular
Phase
Observational
Started
2026-02-24
Last updated
2026-08-11

Condition(s) studied

Venous Embolism of Lower Extremities (Diagnosis)Arterial Embolism and ThrombosisAcute DVT of Lower ExtremityChronic DVT of Lower ExtremityDVTDeep Vein Thrombosis LegThrombus in the Peripheral Venous VasculaturePeripheral Arterial DiseaseAcute Limb IschemiaLower Extremity Acute Limb IschemiaLE ALI

Investigational drug(s) / intervention(s)

Liberant Thrombectomy System

Liberant Thrombectomy System: The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Study summary

The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria: 1. Patient treated is age ≥ 22 years at the time of procedure 2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure

Primary outcome measure(s)

  • Rate of Device related Serious Adverse Event at Index procedure — Index Procedure
    An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
  • Rate of technical success at Index procedure — Index procedure
    Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
  • Rate of Procedural Success at Index procedure — Index procedure
    Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure

Trial sites (4)

FacilityCityRegionStatus
MedStar Health Washington D.C. District of Columbia Recruiting
Naples Comprehensive Health Naples Florida Recruiting
Mount Sinai New York New York Recruiting
Baylor Heart Hospital Of Plano Plano Texas Recruiting

More Medtronic Endovascular trials in the USA

Onyx™ Liquid Embolic IDE Clinical Study Recruiting
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils Enrolling by invitation

Other trials for the same condition

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants Recruiting
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) Active, not recruiting
Pounce™ Thrombectomy System Retrospective Registry Recruiting
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07335341 on ClinicalTrials.gov ↗ ← All trials in the USA